Prior Authorization Form

CAREFIRST

Eysuvis

This fax machine is located in a secure location as required by HIPAA regulations.
Complete/review information, sign and date. Fax signed forms to CVS/Caremark at **1-888-836-0730**.
Please contact CVS/Caremark at **1-800-294-5979** with questions regarding the prior authorization process.
When conditions are met, we will authorize the coverage of Eysuvis.

Drug Name (select from list of drugs shown)

Eysuvis 0.25% Ophth Susp (loteprednol etabonate)

Quantity Frequency Strength

Route of Administration Expected Length of Therapy

Patient Information

Patient Name: _____

Patient ID: _____

Patient Group No.: _____

Patient DOB: _____

Patient Phone:

Prescribing Physician

Physician Name: _____

Physician Phone: _____

Physician Fax: _____

Physician Address: _____

City, State, Zip: _____

Diagnosis: _____ **ICD Code:** _____

Comments: _____

Please circle the appropriate answer for each question.

1. Is the requested drug being prescribed for the treatment of the signs and symptoms of dry eye disease?	Y N
[If Yes, then go to 2. If No, then no further questions.]	
2. Is the requested drug being prescribed for short-term use (up to two weeks)?	Y N
[If Yes, then go to 3. If No, then no further questions.]	
3. Has the patient experienced an inadequate treatment response to an artificial tears product?	Y N
[If Yes, then go to 6. If No, then go to 4.]	

4.	Has the patient experienced an intolerance to an artificial tears product?	Y N
	[If Yes, then go to 6. If No, then go to 5.]	
5.	Does the patient have a contraindication that would prohibit a trial of an artificial tears product?	Y N
	[If Yes, then go to 6. If No, then no further questions.]	
6.	Does the patient require more than the plan allowance of 2 bottles per 90 days of the requested drug?	Y N
	[No further questions]	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date